By Fineline Cube AstraZeneca (NYSE: AZN) announced positive results from its comprehensive Phase III clinical program for efzimfotase alfa (ALXN1850), an investigational enzyme replacement therapy (ERT) for hypophosphatasia (HPP), demonstrating favorable safety and efficacy across pediatric and adult patient populations.
Clinical Trial Portfolio
| Study | Population | Comparator | Key Results |
|---|---|---|---|
| MULBERRY | Treatment-naïve pediatric (2 to <12 years) | Placebo | Statistically significant improvement in skeletal health |
| CHESTNUT | Pediatric switchers from Strensiq (2 to <12 years) | Strensiq (asfotase alfa) | Maintained skeletal benefits with improved dosing regimen |
| HICKORY | Treatment-naïve adolescents/adults (≥12 years) | Placebo | Numerical improvement in 6MWT; significant fatigue reduction |
Drug Profile & Innovation
- Molecule: Efzimfotase alfa (ALXN1850) – investigational enzyme replacement therapy
- Target Indication: Hypophosphatasia (HPP) – rare metabolic bone disorder
- Key Advantages:
- Lower injection volume compared to Strensiq (asfotase alfa)
- Less frequent dosing schedule
- Broader patient population coverage
- Development Stage: Phase III completed across multiple age groups
Detailed Clinical Outcomes
MULBERRY Trial (Pediatric, Treatment-Naïve)
- Population: Children aged 2 to <12 years with HPP
- Primary Endpoint: Skeletal health improvements
- Result: Statistically significant and clinically meaningful improvements versus placebo
- Significance: First robust evidence of efficacy in treatment-naïve pediatric HPP patients
CHESTNUT Trial (Pediatric, Strensiq Switchers)
- Population: Children aged 2 to <12 years switching from Strensiq
- Primary Assessment: Safety and tolerability
- Secondary Endpoints: RGI-C (Radiographic Global Impression of Change) and RSS (Rachitic Severity Score)
- Results: Well-tolerated with maintained treatment benefits on skeletal health at Week 25 compared to Strensiq
HICKORY Trial (Adolescent/Adult, Treatment-Naïve)
- Population: Patients aged 12 years and older with HPP
- Primary Endpoint: Six-minute walk test (6MWT) at Week 25
- Result: Numerical improvement that did not reach statistical significance due to higher-than-expected placebo performance
- Secondary Endpoint: FACIT-Fatigue scale showed nominally significant improvements in overall study population
Market Opportunity & Competitive Landscape
- HPP Prevalence: Ultra-rare disease affecting approximately 1 in 100,000 live births
- Current Standard: Strensiq (asfotase alfa) – Alexion’s (now AstraZeneca) existing ERT requiring frequent, high-volume injections
- Unmet Needs:
- Improved convenience through reduced injection burden
- Expanded access to adolescent and adult populations
- Better tolerability profile
- Commercial Potential: Orphan drug designation likely to provide market exclusivity and premium pricing
Strategic Significance for AstraZeneca
- Rare Disease Franchise: Strengthens AstraZeneca’s position in ultra-rare metabolic disorders following Alexion acquisition
- Lifecycle Management: Potential to capture existing Strensiq patients seeking improved dosing convenience
- Market Expansion: Addresses previously underserved adolescent and adult HPP population
- Regulatory Pathway: Comprehensive Phase III data package supports global regulatory submissions
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory submissions, and commercial potential for efzimfotase alfa. Actual results may differ due to risks including regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech